1. Home
  2. RIGL vs AWP Comparison

RIGL vs AWP Comparison

Compare RIGL & AWP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • AWP
  • Stock Information
  • Founded
  • RIGL 1996
  • AWP 2007
  • Country
  • RIGL United States
  • AWP United States
  • Employees
  • RIGL N/A
  • AWP N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • AWP Trusts Except Educational Religious and Charitable
  • Sector
  • RIGL Health Care
  • AWP Finance
  • Exchange
  • RIGL Nasdaq
  • AWP Nasdaq
  • Market Cap
  • RIGL 335.5M
  • AWP 346.7M
  • IPO Year
  • RIGL 2000
  • AWP N/A
  • Fundamental
  • Price
  • RIGL $38.85
  • AWP $3.99
  • Analyst Decision
  • RIGL Buy
  • AWP
  • Analyst Count
  • RIGL 5
  • AWP 0
  • Target Price
  • RIGL $38.20
  • AWP N/A
  • AVG Volume (30 Days)
  • RIGL 995.6K
  • AWP 331.5K
  • Earning Date
  • RIGL 08-05-2025
  • AWP 01-01-0001
  • Dividend Yield
  • RIGL N/A
  • AWP 12.48%
  • EPS Growth
  • RIGL N/A
  • AWP N/A
  • EPS
  • RIGL 5.43
  • AWP N/A
  • Revenue
  • RIGL $267,921,000.00
  • AWP N/A
  • Revenue This Year
  • RIGL $59.93
  • AWP N/A
  • Revenue Next Year
  • RIGL N/A
  • AWP N/A
  • P/E Ratio
  • RIGL $7.15
  • AWP N/A
  • Revenue Growth
  • RIGL 105.62
  • AWP N/A
  • 52 Week Low
  • RIGL $12.66
  • AWP $3.06
  • 52 Week High
  • RIGL $43.72
  • AWP $4.20
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 68.57
  • AWP 63.22
  • Support Level
  • RIGL $39.00
  • AWP $3.95
  • Resistance Level
  • RIGL $42.08
  • AWP $4.01
  • Average True Range (ATR)
  • RIGL 2.32
  • AWP 0.04
  • MACD
  • RIGL -0.37
  • AWP 0.01
  • Stochastic Oscillator
  • RIGL 53.26
  • AWP 85.71

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About AWP abrdn Global Premier Properties Fund of Beneficial Interest

Aberdeen Global Premier Properties Fund is a diversified, closed-end management investment company. Its objective is to seek high current income and capital appreciation. It predominantly invests in equity and debt securities of domestic and foreign issuers which are principally engaged in the real estate industry, real estate financing or control real estate assets. Its portfolio of investments consists securities of Industrial REITs, Retail REITs, Data Center REITs, Health Care REITs and others.

Share on Social Networks: